GE HealthCare has received FDA clearance for SIGNA MAGNUS, a 3T MR system focused on high-resolution brain imaging, offering enhanced capabilities for neurological, oncological, and psychiatric research.

By utilizing GE HealthCare's most advanced 3T MR imaging technology to enhance detail and clarity in brain microstructures and functions, SIGNA MAGNUS is poised to help expand understanding of neurological disorders, such as Alzheimer's, and improve diagnostic capabilities.

“Obtaining FDA clearance further validates our commitment to not only innovating but also in delivering clinical technologies that have real-world impact,” said Jason Polzin, GE HealthCare's GM of MR Applications Platform and Research Technologies.
The MR scanner features HyperG gradient technology, which supports superior gradient performance, allowing for the detection of finer details previously beyond reach. Its innovative asymmetric gradient design optimizes diffusion performance, crucial for advanced research into brain architecture.

The MAGNUS (Microstructure Anatomy Gradient for Neuroimaging with Ultrafast Scanning) gradient coils were initially showcased at the International Society for Magnetic Resonance in Medicine (ISMRM) virtual meeting in 2020 as part of a study between the GE Research Center and the Uniformed Services University, the U.S. government’s health sciences university. The MAGNUS gradient coils were used to assess military personnel suffering from acute and chronic mild TBI at a major U.S. military treatment facility, with the goal being to find new imaging biomarkers for diagnosing cases of mild TBI.

Several academic and research institutions, including Walter Reed National Military Medical Center, the University of Iowa, University of Wisconsin-Madison, and Brigham and Women’s Hospital, have been utilizing SIGNA MAGNUS for investigational purposes.

Alzheimers/Neurology Homepage